Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group
A Ohtsu, H Baba, Y Sakata, Y Mitachi, N Horikoshi, K Sugimachi, T Taguchi, A Ohtsu, H Baba, Y Sakata, Y Mitachi, N Horikoshi, K Sugimachi, T Taguchi
Abstract
This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). Sixty-three patients with measurable metastatic colorectal carcinoma were enrolled into the study. None of the patients had received prior chemotherapy except for adjuvant setting. S-1 was administered orally twice daily at a standard dose of 80 mg m(-2) day(-1) for 28 days followed by a 14-day rest. This agent is continued until disease progression, unaccepted toxicity, or patient refusal. Twenty-two (35%) of the 62 eligible patients achieved PR with a 95% confidence interval of 25-48%. Five of the 10 patients with a history of adjuvant chemotherapy achieved partial remission. The median survival time was 12 months. Major adverse reactions included myelosuppressive and gastrointestinal toxicities, though their incidence of grade 3 or 4 being 13% in neutropenia and less than 10% in the others. None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical modulation with easily manageable toxicity.
References
- Cancer Chemother Pharmacol. 1997;39(3):205-11
- J Clin Oncol. 1997 Jan;15(1):110-5
- J Clin Oncol. 1998 Jul;16(7):2557-67
- J Clin Oncol. 1998 Aug;16(8):2877-85
- Eur J Cancer. 1998 Oct;34(11):1715-20
- Oncology. 1999 Oct;57(3):202-10
- Cancer Res. 1979 Jul;39(7 Pt 1):2406-13
- Gan. 1979 Jun;70(3):353-9
- N Engl J Med. 1985 Jul 25;313(4):245-9
- Cancer Res. 1987 Apr 15;47(8):2203-6
- Jpn J Cancer Res. 1987 Jul;78(7):748-55
- J Clin Invest. 1988 Jan;81(1):47-51
- J Clin Oncol. 1989 Oct;7(10):1407-18
- Cancer Res. 1990 Jan 1;50(1):197-201
- Br J Cancer. 1990 Dec;62(6):1023-5
- Cancer. 1992 Feb 15;69(4):893-900
- Cancer Res. 1993 Sep 1;53(17):4004-9
- Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11064-8
- J Clin Oncol. 1994 Nov;12(11):2296-300
- J Clin Oncol. 1995 Jun;13(6):1303-11
- J Clin Oncol. 1995 Jul;13(7):1663-70
- Cancer Res. 1996 Jun 1;56(11):2602-6
- Gan To Kagaku Ryoho. 1997 Dec;24(15):2253-64
Source: PubMed